Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05782244CT.gov Sildenafil for Microvasculopathy in Chronic TBI | — | Recruiting | — | — | — |
NCT03598140CT.gov Sildenafil Treatment for Mild TBI | — | Terminated | — | — | — |
NCT03417492CT.gov Cerebrovascular Reactivity in American Football Players | — | Terminated | — | — | — |
NCT02990078CT.gov Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury | — | Terminated | — | — | — |
NCT02114775CT.gov Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI) | — | Completed | — | — | — |
NCT01762475CT.gov Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sildenafil (this asset) | University of Pennsylvania | P2 | CCC · 55 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Lacto-Flavin | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | BB |
| Serostim | Anhui Provincial Hospital | P4 | BB |
| Fentanyl | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Sildenafil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pulmonary Hypertension | — | P4 | BB · 71 |
| Sickle Cell Disease | — | P4 | BB · 68 |
| Erectile Dysfunction | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sildenafil in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sildenafil-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →